IMMP
IMMUTEP Ltd
NASDAQ · Healthcare · Biotechnology · AU
$0.29
−9.21%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.31
From 52W high−90.95%
Volume564704.00
Market cap$42.40M
P/E (TTM)—
P/S (TTM)3.6x
Div yield—
Key dataSep 18, 2026
Open
$0.31
From 52W high
−90.95%
Volume
564704.00
Market cap
$42.40M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
29.4
MomentumView details →
1D Return
−9.21%
YTD Return
−90.00%
SummaryUpdated Jun 1, 2026
Immutep Limited (NASDAQ:IMMP) is an Australian biotechnology company founded in 1987 and originally known as Prima BioMed Ltd before rebranding in November 2017. The company is headquartered in Sydney, Australia, and has been publicly traded since its IPO in April 2012. Immutep focuses on developing innovative immunotherapy treatments for cancer and autoimmune diseases, with its lead drug candidate currently in Phase IIb clinical trials for metastatic breast cancer treatment.
Similar companies
Latest newsMore news →
Immutep outlined a refocused development strategy for eftilagimod alfa (efti), concentrating future registration-directed work on head and neck squamous cell carcinoma (CPS below 1) and neoadjuvant soft tissue sarcoma, following a root cause analysis of the discontinued TACTI-004 study.10d agoA securities class action has been filed against Immutep Limited alleging violations of federal securities laws.111d ago